I am actually not sure as to the actual size of the potential market. I know that there is a very sizeable population of patients with lupus who suffer from the terrible side effect of nephritis. I know that this new product in conjunction with low dose steroids and the SOC yields results apparently much better than the current SOC alone as should be validated again with the 48 week results of phase 2B to be announced in February. I know that the market cap is very low and that the institutions have yet to jump in probably due to their restrictive criteria. Even if the market is as low as 125 million in revenue, at 5x revenue that would be 625 million as a market cap, much higher than now. I suspect that the probable market for this drug is much more than 125 million but would welcome input from North on this issue.
News 
Market Data 
Discover 
